# A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above

> **NCT05365724** · PHASE1,PHASE2 · UNKNOWN · sponsor: **China National Biotec Group Company Limited** · enrollment: 280 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Omicron COVID-19 Vaccine (Vero Cell), Inactivated

## Key facts

- **NCT ID:** NCT05365724
- **Lead sponsor:** China National Biotec Group Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-01
- **Primary completion:** 2023-10-01
- **Final completion:** 2023-10-01
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2023-06-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05365724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05365724, "A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05365724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*